









MENU \

113. HEMOGLOBINOPATHIES, EXCLUDING THALASSEMIA—BASIC AND TRANSLATIONAL SCIENCE: POSTER I | DECEMBER 7, 2017

Longitudinal Monitoring of RBC Adhesion in Patients with SCD Is **Heterogeneous and Clinically informative**

Erdem Kucukal, MS, Erina Quinn, Charlotte Yuan, Constance Fung, Jane A. Little, MD, Umut A. Gurkan, PhD



Blood (2017) 130 (Supplement 1): 953.

https://doi.org/10.1182/blood.V130.Suppl 1.953.953





Abstract

Abnormal adhesion of red and white blood cells (RBCs and WBCs) to the endothelium is a hallmark of sickle cell disease (SCD), and is not well elucidated. We have found that RBC adhesion profiles for different adhesion ligands on the (sub) endothelium, drawn at clinical baseline, associate with biomarkers of disease severity such as LDH and absolute reticulocyte counts. However, these adhesion profiles may change significantly for an individual over time. To better understand the implications of RBC adhesion relative to disease status, we monitored longitudinal RBC adhesion to laminin (LN), drawn during baseline clinic visits, in individual patients.

82 blood samples from 31 SCD patients (Table 1, 27 HbSS and 4 HbSS HPFH; 16 males and 15 females) were collected at the University Hospitals Seidman Cancer Center/CWRU in Cleveland, OH over the study period between October 2014 and July 2017. Adhesion experiments were performed by perfusing whole blood samples through LN-immobilized microchannels and quantifying the number Skip to Main Content of additional strains of adherent RBCs in the channels following a rinse at physiological flow conditions. Consequently,



stably high (>500), and non-stable. Patients with non-stable adhesion had adhesion to LN that fluctuated between low and high.

We observed a higher mean LDH level in stably high patients compared to stably low patients (Fig. 1A, mean = $614.9\pm165.4 \text{ vs } 361.4\pm48$, p=0.059, one-way ANOVA). Compared with stably low adhesion, patients with stably high adhesion had significantly greater absolute reticulocyte counts (Fig. 1B, p=0.001, one-way ANOVA). Patients with non-stable RBC adhesion to LN show an association between individual LDH levels and adhesion at that time (Fig. 1C through 1H). However, an association was absent during several time periods, such as patient 67, 65, and 5 (Fig. 1E, 1F, and 1G).

Our data showed that SCD patients can broadly be separated into three groups based on the changes in their longitudinal RBC adhesion levels in LN-functionalized microchannels. Patient clinical data, particularly hemolytic biomarkers (LDH and absolute reticulocyte counts), correlated with the quantitative RBC adhesion numbers for patients with low and high adhesion. Furthermore, the general adhesion profile of patients with non-stable adhesion over time were generally consonant with their LDH levels, rather than pain profiles, which may suggest a hemolytic phenotype in those patients with increased RBC adhesion to LN, which may be pathophysiologically relevant. We are testing whether adhesion by RBCs to LN could be a useful surrogate for disease activity in therapeutic studies of anti-adhesive therapy.

Acknowledgments: This work was supported by grant R01HL133574 from the National Heart Lung and Blood Institute.


Figure 1. Longitudinal analysis of RBC adhesion to LN in SCD patients. Patients were categorized into three groups: stably low (<500), stably high (>500), and non-stable. Steady high patients had elevated LDH levels with a non-significant correlation (A) as well as significantly higher absolute reticulocyte counts. Change of RBC adhesion numbers to LN associated with patient LDH levels over time for (C) UPN 1, (D) UPN 27, (E) UPN 67, (F) UPN 65, (G) UPN 5, and (H) UPN 33. (UPN: Unique Patient Number)

Figure 1

Skip to Main Content







	Mean ± St. Err.	Range
Age	35.2 ± 1.4	19-73
Hgb (g/dL)	8.5 ± 0.2	5.5-12
WBC (10°/L)	12.0 ± 0.5	4,2-27.3
Absolute Neutrophil Count (10 ⁶ /L)	6772 ± 359	720-16560
Reticulocyte Count (10°/L)	362.8 ± 24.5	21-971
Lactate Dehydrogenase (U/L)	424.8 ± 30.0	157-1624
Ferritin (µg/L)	1923±211	11-2993
Hemoglobin S (%)	65.8 ± 2.6	3.6-94
Hemoglobin A (%)	18.4 ± 2.5	1.2-79
Hemoglobin F (%)	7.3 ± 0.8	0.1-25.5

VIEW LARGE DOWNLOAD SLIDE

Disclosures

Little: Hemex Health: Equity Ownership. Gurkan: Hemex Health: Employment, Equity Ownership.

Topics: adhesions, heterogeneity, biological markers, laminin, ligands, pain, severity of illness, sickle cell anemia, reticulocyte count, adhesives

Skip to Main Content Author notes



© 2017 by The American Society of Hematology

Sign in via your Institution

Add comment

Volume 130, Issue Supplement 1

December 7 2017

Previous Article

Next Article >

Advertisement

Sign in via your Institution

Potential Articles of Interest

Adhesion of Sickle RBCs to Heme-Activated Endothelial Cells Correlates with Patient Clinical Phenotypes

Kucukal, Blood, 2017

Patient-Specific Adhesion of Sickle Red Blood Cells in Shear-Gradient Microscale Flow

Kucukal et al., Blood, 2017

Skip to Main Content

Hypoxia Responsiveness in RBCs from Patients with Sickle Cell Disease Associates with a More Severe Clinical Phenotype



Partial Treatment Response to Alectinib in Metastatic Non-small Cell Lung Cancer with KIDINS220-ALK Fusion

Yanna Lei et al., Precision Clinical Medicine, 2023

Expression differences of miR-200c, miR-19a and miR-155 in gefitinib sensitive and drug resistant NSCLC patients and their effects on prognosis

Liu Pei et al., Journal of International Oncology, 2021

A novel immunogenomic signature to predict prognosis and reveal immune infiltration characteristics in pancreatic ductal adenocarcinoma

Ang Li et al., Precision Clinical Medicine, 2022

Powered by **TREND MD**

View Metrics

Cited By

Google Scholar



Article Activity Alert

First Edition Alert

Latest Issue Alert

Skip to Main Content

Advertisement



Abstract



Current Issue

First edition

All Issues

Collections

Abstracts

Authors

Submit to Blood

About Blood

Subscriptions

Public Access

Permissions

Alerts

Contact Us

Newsroom

Blood Classifieds

Advertising in Blood

Terms and Conditions

Twitter

Skip to Main Content

American Society of Hematology / 2021 L Street NW, Suite 900 / Washington, DC 20036 /



Abstract

ASH Publications

Blood Blood Advances Hematology, ASH Education Program ASH Clinical News ASH-SAP The Hematologist

American Society of Hematology

ASH Home
Research
Education
Advocacy

Meetings Publications ASH Store

Copyright ©2023 by American Society of Hematology

Privacy Policy Cookie Policy Terms of Use Contact Us